AI Article Synopsis
- The placental growth factor (PlGF) and its soluble receptor (sFlt-1) are important molecules released by the placenta during pregnancy, which play key roles in blood vessel formation.
- Preeclampsia, affecting 2-7% of pregnant women, is marked by high blood pressure and protein in urine, with an altered sFlt-1/PlGF ratio indicating potential diagnosis and risk, especially if it occurs early.
- This work aims to provide updated insights on PlGF and sFlt-1, their functions and changes during pregnancy and preeclampsia, as well as available blood tests to measure their levels.
Article Abstract
The placental growth factor (PlGF) and its soluble receptor (sFlt-1) are circulating angiogenic factors. During pregnancy these factors are released by the placenta into the maternal circulation. Preeclampsia affects 2-7% of pregnant women according to their risk factors and is characterized by high blood pressure and the onset of de novo proteinuria in the second half of pregnancy. Alterations of the sFlt-1/PlGF ratio in preeclampsia correlate with the diagnosis and adverse outcomes, particularly when the disease presents prematurely (<34 weeks). These factors can be assayed in maternal blood and measuring the sFlt-1/PlGF ratio is now available. We propose in this work to update the knowledge of these two molecules, describe their roles and evolution during normal pregnancy and preeclampsia, and finally to focus on the available assays.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/abc.2016.1158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!